Antengene Corporation

Antengene Corporation Limited, a biopharmaceutical company, engages in the development of oncology therapies in China. It offers ATG-016, a second generation XPO1 inhibitor, which is in Phase I/II clinical study in patients with solid tumors; ATG-527 (Verdinexor) that has completed Phase I evaluation for chronic human viral infections; ATG-019, a dual PAK4/NAMPT inhibitor for the treatment of NHL and advanced solid tumors; ATG-017, an ERK1/2 inhibitor for the treatment of advanced solid tumors and hematologic malignancies; ATG-010 (selinexor), a SINE compound targeting XPO1; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is in Phase I study for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma, as well as ATG-008 (onatasertib), an orally available mTOR kinase inhibitor for the treatment of solid tumors harboring NFE2L2, STK11, RICTOR, and other specific genetic alterations. Its products in pre-clinical stage include ATG-037 (CD73 inhibitor) for patients with advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031 (CD24 antibody); ATG-027 a B7H3/PD-L1 bispecific antibody; ATG-032 (LILRB antibody); and ATG-041, an Axl-Mer inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.

Antengene Corporation was founded in 2002 by a group of experienced oncologists, biochemists and pharmaceuticals with a vision of developing innovative and cutting-edge therapeutics for various cancers. Since its founding, Antengene has become a leader in the discovery, development and commercialization of novel drugs for treating various cancer indications. The company has developed a deep portfolio of oncology drugs in numerous therapeutic areas including hematological, gastrointestinal and solid tumor indications.

To discover and develop innovative, transformative therapies for cancer that are grounded on strong science and evidence-based medicine.

Our vision is to be a premier drug discovery and development company creating innovative therapies to improve the lives of patients fightingcancer and other diseases.

To discover and develop innovative, transformative therapies for cancer that are grounded on strong science and evidence-based medicine.

Our vision is to be a premier drug discovery and development company creating innovative therapies to improve the lives of patients fightingcancer and other diseases.

Antengene Corporation

Share

Contacts

Follow Us

Antengene Corporation

Share

Contacts

Follow Us